Medical Doctor (MD), 1981; Master in Science (MsS), 1986, and PhD, 1993 at University of São Paulo (USP). Has experience in Clinical Medicine, focusing on Hematology, Hemotherapy, and Cell Therapy acting on the following subjects: transfusion medicine, infections transmitted by transfusions, molecular biology, cell therapy, stem cells, and biotechnology (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The Instituto Butantan (IBu) is a research, innovation and production institute with national and world recognition, whose fundamental mission is to meet the demands of public health, contributing to the promotion of the population's well-being. It has an important collection of biological material, including primary and human cell lineages and cultures, human biological material obtained…
The Nucleus of Cellular Therapy - NuTeC will be founded on the union of the Regional Blood Center of Ribeirão Preto (Hemocentro RP) and Butantan. Hemocentro RP expertise in cellular therapy will be added to Butantan excellence in the development and production of health applied products to develop CAR T cell therapy. The activities to be conducted by NuTeC are aligned with the scope of th…
The Regional Blood Center of Ribeirão Preto is a health care, education, and research organ linked to the Ribeirão Preto Medical School. It hosts the CTC- Center for Cell-based Therapy - CEPID - FAPESP and INCTC - National Institute of Science and Technology on Stem Cells and Cell Therapy CNPQ/FAPESP. The Regional Blood Center has 11.804 m2 of constructed area, of which 5.217 m2 are desig…
(Only some records are available in English at this moment)
The Regional Blood Center of Ribeirão Preto is a health care, education, and research organ linked to the Ribeirão Preto Medical School. It hosts the CTC- Center for Cell-based Therapy - CEPID - FAPESP and INCTC - National Institute of Science and Technology on Stem Cells and Cell Therapy CNPQ/FAPESP. The Regional Blood Center has 11.804 m2 of constructed area, of which 5.217 m2 are desi…
After months of the worldwide spread of the SARS-CoV-2 novel coronavirus, it has become clear that the development and manufacturing of a safe and effective vaccine is a promising public policy strategy to combat the pandemic that will allow for the complete reopening of the economy and the prevention of new epidemic waves. Instituto Butantan is a century-old institution dedicated to the …
The Regional Blood Center of Ribeirão Preto is a center of medical care, education and research linked to the School of Medicine of Ribeirão Preto. It holds the CTC- Center for Cell-based Therapy- CEPID-FAPESP and INCTC - National Institute of Science and Technology in Stem Cell and Cell Therapy in Cancer - CNPq/FAPESP. The Hemocentro Foundation of Ribeirão Preto has independent administr…
(Only some records are available in English at this moment)
The cancer immunotherapies have shown promising results compared to the conventional therapies, such as the adoptive therapy of T lymphocytes expressing chimeric antigen receptors (CAR) in the treatment of hematological malignancies. However, the therapeutic efficacy of CAR-T lymphocytes against solid tumors, which represent the majority of tumors, is still insufficient. One of the reason…
(Only some records are available in English at this moment)
(Only some records are available in English at this moment)
The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Although CAR-T cell therapy has demonstrated encouraging results with complete response rates of 70%-90% in patients with B cell malignancies, this new therapeutic modality is not yet fully mastered nor optimized. Some rec…
Inhibitory antibodies development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and decreased life quality. Approximately 5% of patients with hemophilia B and 20 to 30% of patients with severe hemophilia A, who use factor IX (FIX) and factor VIII (FVIII) replacement therapy, respectively, develop ant…
| 4 / 4 | Ongoing research grants |
| 12 / 8 | Completed research grants |
| 6 / 6 | Ongoing scholarships in Brazil |
| 45 / 20 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 70 / 41 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID